VTv Therapeutics trades as part of the biotechnology industry and healthcare sector. The company CEO is Stephen L. Holcombe. vTv Therapeutics Inc is a biopharmaceutical company engaged in drug discovery and development. Its therapies are intended to treat diseases such as Alzheimer’s and type-II diabetes. Its other products include TTP399, type II diabetes drug candidate.

SeekingAlpha:  Daily Insider Ratings Round Up 5/16/19

Historical Performance:

Over the last five trading days, VTVT shares returned 9.43% and in the past 30 trading days it returned 19.18%. Over three months, it changed -30.40%. In one year it has changed 2.96% and within that year its 52 week high was 6.09 and its 52 week low was 0.68. VTVT stock is 154.61% above its 52 week low.

Our calculations result in a 200 day moving average of 1.94 and a 50 day moving average of 1.58. Right now, VTVT stock is trading -10.49% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Daily Insider Ratings Round Up 5/16/19


The company has a market cap of $90.0m with 51.7m shares outstanding and a float of 51.6m shares. Trading volume was 642,526 shares and has experienced an average volume of 907,103 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for VTv Therapeutics was -0.72 which ended on 31st of December 2018.

1stQtr 2019 -0.264thQtr 2018 -0.103rdQtr 2018 -0.062ndQtr 2018 -0.311stQtr 2018 -0.30

The next earnings report will be: 05-29-2019

EPS growth is an important number as it indicates the future prospects of VTv Therapeutics; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 240.00% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 10.60% of institutional ownership.

The beta was calculated to be -3.71.

SeekingAlpha:  Varonis Systems’ (VRNS) CEO Yaki Faitelson on Q1 2019 Results – Earnings Call Transcript

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -95.90%, price-to-sales is 8.38 and.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 0  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 0  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here